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Abstract 
Background: There are inconsistent data about the role of serum phospholipid fatty acid composition in patients 
with type 2 diabetes (T2DM) and atherosclerotic cardiovascular disease (ASCVD). The aim of the study was to inves‑
tigate the relationship between serum phospholipid fatty acid composition, systemic low‑grade inflammation, and 
glycemic control in high‑risk T2DM patients.
Methods: Seventy‑four patients (26% women, mean age 65.6 ± 6.8 years) with T2DM (median diabetes duration 
10 years) and documented ASCVD (74 with coronary artery disease, 26 with peripheral arterial disease) were enrolled 
in the study. Baseline  HbA1c was estimated using turbidimetric inhibition immunoassay. According to the median 
value of  HbA1c the patients were grouped into those with  HbA1c < 7.0% (< 53 mmol/mol) (n = 38) and those with 
 HbA1c ≥ 7.0% (≥ 53 mmol/mol) (n = 36). Serum phospholipid fatty acids were measured with gas chromatography.
Results: Patients with  HbA1c ≥ 7.0%, compared with those with  HbA1c < 7.0% had similar composition of saturated 
and monounsaturated fatty acids in serum phospholipids, but had higher concentrations of linoleic acid (LA) and 
higher n‑6/n‑3 polyunsaturated fatty acid (PUFA) ratio as well as lower levels of eicosapentaenoic acid (EPA), total 
n‑3 PUFAs, and the EPA/arachidonic acid ratio. We found that LA (r = 0.25; p = 0.03) and n‑6/n‑3 PUFA ratio (r = 0.28; 
p = 0.02) were positively correlated with  HbA1c. Multivariate logistic regression analysis showed that n‑6/n‑3 PUFA 
ratio, hsCRP and T2DM duration were independent predictors of worse glycemic control in patients with T2DM and 
ASCVD.
Conclusions: This study showed that glycemic control in high‑risk T2DM patients with ASCVD was significantly asso‑
ciated with unfavorable serum phospholipid n‑6/n‑3 PUFA ratio and greater systemic inflammation.
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Background
Cardiovascular diseases are the main complications of 
type 2 diabetes mellitus (T2DM), accounting for approxi-
mately two-thirds of deaths in T2DM patients [1–4]. The 
underlying mechanisms linking T2DM with atheroscle-
rotic cardiovascular disease (ASCVD) remain not fully 
understood. There is strong evidence that classic risk fac-
tors do not explain the higher risk of ASCVD in T2DM 
patients [5].
Multiple pathophysiologic processes may contribute 
to ASCVD in T2DM including hyperglycemia, hypogly-
cemia, insulin resistance or hyperinsulinemia, dyslipi-
demia, chronic low-grade inflammation, oxidative stress, 
endothelial dysfunction, vascular calcification, and hyper-
coagulability [4–11]. Numerous experimental and clinical 
studies have shown the close relationship between dysgly-
cemia and increased risk for ASCVD, with an estimated 
11–16% increase in cardiovascular events for every 1% 
increase in glycated hemoglobin  (HbA1c) level [4]. It has 
been shown that  HbA1c levels of ≥ 7.0% (≥ 53 mmol/mol) 
were associated with unfavorable cardiovascular outcomes 
in T2DM patients with established atherosclerosis [12].
Epidemiological studies have demonstrated that serum 
fatty acid (FA) profile is an independent risk factor for 
ASCVD [5, 13]. Much evidence has been accumulated 
indicating that dietary or blood FA composition was sig-
nificantly associated with impaired endothelial function, 
systemic inflammation, oxidative stress, β-cell dysfunction, 
and insulin resistance [14]. It has been also demonstrated 
that serum/plasma FA profiles are related to an increased 
risk of T2DM and its macrovascular complications [14].
Long-chain polyunsaturated fatty acids (PUFAs) and their 
derivatives can modulate many metabolic and inflammatory 
pathways in diabetic and nondiabetic subjects [15–19]. Epi-
demiological evidence has indicated that populations with 
high fish consumption had less risk of diabetes and ASCVD 
[20]. Although beneficial effects of PUFAs have been widely 
documented, the results of ORIGIN (Outcome Reduction 
with Initial Glargine Intervention) study, the world’s long-
est and largest randomized clinical trial in T2DM and pre-
diabetes, showed that n-3 PUFA supplementation did not 
affect the risk of death from cardiovascular causes in T2DM 
patients [21]. Thus, the recently published science advisory 
from the American Heart Association does not recom-
mend supplementation with n-3 PUFAs for individuals with 
T2DM to prevent coronary artery disease (CAD) [20]. On 
the other hand, the treatment with n-3 PUFA supplements 
seems to be reasonable for the secondary prevention of 
CAD deaths among patients with prior CAD [20].
There are limited and inconsistent data about the role 
of serum phospholipid FA composition in the patho-
physiology of T2DM and diabetes-related ASCVD. In 
addition, very little is known regarding associations of 
dysglycemia with serum FA profiles and chronic inflam-
mation in T2DM patients with documented ASCVD.
Therefore, the aim of the present study was to investigate 
the relationship between FA composition in serum phos-
pholipids, systemic low-grade inflammation, and glycemic 
control in patients with T2DM and established ASCVD.
Methods
Patients
The study design and population sampling are described 
in detail elsewhere [22]. In brief, we assessed 126 fol-
lowing T2DM patients with a history of coronary artery 
disease (CAD) and/or peripheral artery disease (PAD). 
Exclusion criteria were the same as in our previous study 
[22]. Finally, 74 patients with T2DM and established 
CAD and/or PAD were enrolled. The median duration of 
diabetes was 10 (interquartile range [IQR], 6–15) years. 
Diabetic patients were grouped according to the median 
value of  HbA1c into those with  HbA1c < 7.0% (< 53 mmol/
mol) (n = 38 individuals) and those with  HbA1c ≥ 7.0% 
(≥ 53 mmol/mol) (n = 36 patients).
This study was performed according to the Helsinki 
Declaration with the approval of the Ethics Commit-
tee of the Jagiellonian University Medical College (No: 
KBET/190/B/2012). Informed consent was obtained 
from all individual participants included in the study.
Blood sampling and laboratory measurements
Fasting blood samples were obtained between 8 and 
10  a.m. after overnight fast. Samples were processed 
30–60  min after blood collection. Then serum samples 
were stored at −  70  °C until further analysis. Routine 
blood tests, such as complete blood count, lipid profile, 
serum creatinine were carried out by automated labora-
tory techniques.  HbA1c was estimated using turbidimet-
ric inhibition immunoassay (TINIA).
Serum levels of saturated (lauric acid, C12:0; myristic 
acid, C14:0; palmitic acid, C16:0; stearic acid, C18:0; lig-
noceric acid C24:0) and unsaturated FAs: n-7 (palmitoleic 
acid, C16:1), n-9 (oleic acid, C18:1), n-3 (alpha-linolenic 
acid—ALA, C18:3; eicosapentaenoic acid—EPA, C20:5; 
docosahexaenoic acid—DHA, C22:6) and n-6 (linoleic 
acid—LA, C18:2; eicosadienoic acid C20:2; arachidonic 
acid—AA, C20:4) were measured with gas chromatog-
raphy (Agilent Technologies 6890N Network GC Sys-
tems, Wilmington, De., USA). The detailed methods were 
described previously [22]. A concentration of serum FAs 
of phospholipids fraction was expressed in µmol/l.
High-sensitivity C-reactive protein (hsCRP) was meas-
ured by latex nephelometry (Dade Behring, Marburg, 
Germany). The serum levels of interleukin-6 (IL-6) and 
tumor necrosis factor α (TNFα) were evaluated by ELISA 
(R&D Systems, USA).
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Statistical analysis
Categorical variables were presented as numbers and 
percentages. Continuous variables were expressed as 
mean ± standard deviation (SD) or median and interquartile 
range (IQR). Differences between the groups were compared 
using the Student’s t test for normally distributed variables. 
The Mann–Whitney U test was used for non-normally dis-
tributed continuous variables. Data normality was verified by 
the Shapiro–Wilk test. Categorical variables were compared 
by the Fisher’s exact test or by the Pearson’s χ2 test, when 
appropriate. The Spearman’s rank correlation coefficient was 
calculated to measure monotonic trend between two vari-
ables. Stepwise logistic regression analysis was performed 
for determining the independent predictors of poor glyce-
mic control in the study patients. The calibration and dis-
crimination of the developed model were assessed using the 
Hosmer–Lemeshow statistic and the area under the receiver 
operating characteristic curve (AUC), respectively. Two-
sided p values < 0.05 were considered statistically significant. 
All calculations were made using the STATISTICA version 
12.0 PL software package (StatSoft, Inc., Tulsa, Oklahoma).
Results
Baseline characteristics
The baseline characteristics of the study patients, includ-
ing comorbidities and medications are shown in Table 1. 
Of the total population, 66.2, 97.3, 67.6%, were obese, 
hypertensive, and dyslipidemic, respectively. Mean age of 
the study population was 65.6 ± 6.8 years. There were no 
sex differences in demographic and clinical characteristics.
Patients with worse glycemic control at baseline 
 (HbA1c ≥  7.0%) had significantly longer diabetes dura-
tion as compared to those with  HbA1c < 7.0%. There was 
a higher proportion of insulin users among subjects with 
 HbA1c ≥ 7.0% (Table 1).
There were no significant differences in laboratory 
characteristics between studied groups except for higher 
 HbA1c values and increased hsCRP levels in patients with 
worse glycemic control (Table  2). In addition, the indi-
viduals with  HbA1c ≥ 7.0% had lower baseline concentra-
tions of C-peptide.
Fatty acid composition in serum phospholipids
Saturated FAs were the largest fraction in serum phos-
pholipids, followed by n-6 polyunsaturated, n-3 polyun-
saturated, and monounsaturated. Among the single FAs, 
palmitic acid constituted the largest proportion with 
31.2%, followed by AA (17.3%), LA (14.3%), stearic acid 
(13.6%), oleic acid (9.0%), and DHA (9.0%).
There were no relevant intergroup differences in the 
composition of saturated and monounsaturated FAs in 
serum phospholipids (Table 3). T2DM patients with worse 
glycaemic control had significantly higher concentrations 
of LA and higher n-6/n-3 ratio as compared to diabetic 
individuals with  HbA1c  <  7.0%. Furthermore, the study 
patients with  HbA1c ≥ 7.0% had lower levels of EPA, total 
n-3 PUFAs, and the EPA/AA ratio (Fig. 1).
Correlations
We found that LA (r  =  0.25; p  =  0.03) and n-6/n-3 
ratio (r = 0.28; p = 0.02) were positively correlated with 
 HbA1c. No significant correlations were observed with 
regard to other FAs or ratios. In addition, we found a 
significant association between  HbA1c and hsCRP levels 
(r = 0.31; p = 0.008). There were no relevant associations 
between systemic inflammatory markers (hsCRP, IL-6 
and TNFα) and serum phospholipid FA composition in 
T2DM patients with ASCVD.
Univariate and multivariate logistic regression analyses
Statistically significant predictors of poor glycaemic con-
trol  (HbA1c ≥ 7.0%) in the study population are presented 
in Table  4. Multivariate logistic regression analysis dem-
onstrated that n-6/n-3 ratio, hsCRP and T2DM duration 
were independent predictors of worse glycaemic control in 
our patients. The predictive model showed good cross-val-
idated calibration and discrimination with Hosmer–Leme-
show χ2 = 10.73, p = 0.21 and AUC = 0.872, respectively.
Discussion
To our knowledge, this is the first study to show that a 
poor glycemic control  (HbA1c ≥  7.0%) in high-risk dia-
betic subjects with ASCVD is associated with decreased 
levels of EPA, total n-3 PUFAs, and lower EPA/AA ratio 
in the serum phospholipid fraction. Furthermore, the 
patients with worse glycaemic control had increased 
serum concentrations of LA and hsCRP, as well as a 
higher n-6/n-3 ratio. In multivariate analysis, the n-6/
n-3 ratio was the strongest predictor of poor glycaemic 
control, followed by serum hsCRP, and T2DM duration. 
Interestingly, we did not found any relevant intergroup 
differences in the composition of saturated and monoun-
saturated FAs in serum phospholipids.
It is well known that FA composition of serum phos-
pholipids reflects dietary FAs intake during the preceding 
weeks as well as endogenous FAs metabolism, includ-
ing FA synthesis (de novo lipogenesis) and FA desatura-
tion, elongation, retroconversion, and oxidation [23, 24]. 
Recently published data indicate that meal frequency 
may also affect the FA composition of serum phospholip-
ids in patients with T2DM [24].
PUFAs and type 2 diabetes mellitus
Experimental and clinical studies showed that serum FA 
composition is abnormal in T2DM patients [13]. A few 
studies have demonstrated that elevated levels of palmitic 
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(16:0), palmitoleic (16:1n-7), and dihomo-γ-linolenic 
(20:3n-6) acids and decreased concentrations of LA in 
both serum phospholipids and cholesterol esters are 
related to insulin resistance, metabolic syndrome and 
T2DM [23, 25]. Leeson et al. reported that higher levels 
of DHA in erythrocyte phospholipids were associated 
with improved endothelial function, particularly in young 
men who had some of the features of insulin resistance 
[15]. It has been also demonstrated that higher n-3 PUFA 
concentrations in red cell phospholipids were related 
to increased insulin sensitivity and a more favorable 
metabolic profile in middle-aged overweight men [26]. 
Takashi et al. found that T2DM patients with a history of 
prior myocardial infarction had significantly lower serum 
levels of EPA and DHA, as well as the EPA/AA and DHA/
AA ratios as compared to diabetic patients without a his-
tory of myocardial infarction [16].
Table 1 Baseline characteristics of the study population (n = 74)
Data are given as number (percentage) for categorical variables and mean (± standard deviation) or median (IQR) for continuous variables
Italic values indicate significance of p value (p < 0.05)
ACE angiotensin-converting enzyme, ARB angiotensin II receptor blocker, ASA acetylsalicylic acid, CAD coronary artery disease, MI myocardial infarction, MRA 
mineralocorticoid receptor antagonist, PAD peripheral artery disease, PCI percutaneous coronary intervention, PPI proton pump inhibitor, T2DM type 2 diabetes 
mellitus
Variable n = 74 HbA1c < 7.0%
n = 38
HbA1c ≥ 7.0%
n = 36
p value
Age (years) 65.6 ± 6.8 66.0 ± 6.7 65.2 ± 7.1 0.62
Female gender, n (%) 26 (35.1) 10 (26.3) 16 (44.4) 0.10
Hypertension, n (%) 72 (97.3) 37 (97.4) 35 (97.2) 0.97
Hyperlipidemia, n (%) 50 (67.6) 24 (63.2) 26 (72.2) 0.41
Metabolic syndrome, n (%) 74 (100.0) 38 (100.0) 36 (100.0) 1.00
Obesity, n (%) 49 (66.2) 26 (68.4) 23 (63.9) 0.68
Waist circumference (cm) 106.5 ± 9.4 106.7 ± 9.1 106.2 ± 9.8 0.83
Body mass index, kg/m2 31.2 ± 3.6 31.1 ± 3.0 31.3 ± 4.1 0.81
Body fat (%) 34.1 ± 8.6 32.9 ± 7.4 35.4 ± 9.6 0.23
Visceral fat (%) 16.0 ± 4.7 16.4 ± 5.0 15.5 ± 4.2 0.53
Total body water (%) 47.6 (44.2; 49.3) 48.6 (44.2; 49.3) 47.2 (44.0; 49.1) 0.45
Muscle mass (kg) 55.2 ± 10.4 56.1 ± 8.6 54.0 ± 12.7 0.51
Medical history
 T2DM duration (years) 10 (6; 15) 9 (4; 10) 10 (7; 20) 0.02
 CAD, n (%) 74 (100.0) 38 (100.0) 36 (100.0) 1.00
 PAD, n (%) 26 (35.1) 10 (26.3) 16 (44.4) 0.10
 Previous MI, n (%) 28 (37.8) 17 (44.7) 11 (30.6) 0.21
 Previous PCI, n (%) 47 (65.5) 25 (65.8) 22 (61.1) 0.68
Treatment
 ASA, n (%) 74 (100.0) 38 (100.0) 36 (100.0) 1.00
 Clopidogrel, n (%) 33 (44.5) 16 (42.1) 17 (47.2) 0.66
 Beta blocker, n (%) 61 (82.4) 32 (84.2) 29 (80.6) 0.68
 ACE inhibitor or ARB, n (%) 67 (90.5) 33 (86.8) 34 (94.4) 0.26
 Nitrate long acting, n (%) 11 (14.9) 5 (13.2) 6 (16.7) 0.67
 Calcium antagonist, n (%) 32 (43.2) 15 (39.5) 17 (47.2) 0.50
 Statin, n (%) 68 (91.9) 34 (89.5) 34 (94.4) 0.43
 Fibrate, n (%) 1 (1.4) 0 1 (2.8) 0.30
 Diuretic, n (%) 22 (29.7) 9 (23.7) 13 (36.1) 0.24
 MRA, n (%) 9 (12.2) 4 (10.5) 5 (13.9) 0.66
 Metformin, n (%) 49 (66.2) 27 (71.1) 22 (61.1) 0.37
 Sulfonylurea, n (%) 31 (41.9) 19 (50.0) 12 (33.3) 0.15
 Acarbose, n (%) 1 (1.4) 0 1 (2.8) 0.30
 DPP‑IV, n (%) 3 (4.1) 2 (5.3) 1 (2.8) 0.59
 Insulin, n (%) 32 (43.2) 9 (23.7) 23 (63.9) 0.0005
 PPI, n (%) 22 (29.7) 9 (23.7) 13 (36.1) 0.24
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Over the past few decades, numerous investiga-
tions provided evidence for beneficial, cardioprotec-
tive effects of PUFAs, in particular of the n-3 family [13, 
14, 17]. PUFAs, similarly to monounsaturated FAs, may 
decrease oxidative stress, inflammation and endothelial 
dysfunction, influence both insulin secretion and insu-
lin resistance, and reduce diabetes risk [14]. In addition, 
n-3 PUFAs may slow down the progression of pancreatic 
β-cell dysfunction [27]. Several epidemiological studies 
showed that higher serum n-3 PUFA levels may be asso-
ciated with the lower risk of T2DM [14, 20, 28, 29]. How-
ever, data from clinical studies have been conflicting.
It has been demonstrated that n-3 PUFA supplementa-
tion improved insulin sensitivity in Asian population of 
T2DM patients [30]. No benefits were found in Western 
populations [30, 31]. This finding suggests that the favorable 
effect of n-3 PUFAs on insulin sensitivity may be affected 
by ethnicity [31]. On the other hand, Kusunoki et al. found 
no significant association between HOMA-IR, which was 
used as a marker of glycemic control, and levels of EPA, 
DHA, and LA in serum phospholipids of Japanese patients 
with T2DM [32]. However, the authors did not evaluate the 
relationship between HOMA-IR and total levels of n-3 and 
n-6 PUFAs as well as the n-6/n-3 ratio [32]. Sawada et al. 
reported that 6-month EPA supplementation had no effect 
on plasma glucose, HbA1c, and HOMA-R in newly-diag-
nosed impaired glucose metabolism patients with CAD 
[33]. Interestingly, EPA treatment improved postprandial 
hyperglycemia, insulin secretion ability and hypertriglyc-
eridemia, that might have beneficial effects on endothelial 
function and oxidative stress [33]. In our last randomized 
clinical trial, we demonstrated that treatment with 2.0 g of 
EPA-DHA per day for 3 months did not improve glycemic 
control in high-risk diabetic subjects [22]. We suggested 
that longer time of administration and/or higher doses of 
EPA-DHA as well as improvement in oral bioavailability 
of n-3 PUFAs may ameliorate glycemic control in T2DM 
patients.
The present study showed that high-risk T2DM 
patients with intensive glycemic control and  HbA1c 
level < 7.0% had higher levels of EPA and total n-3 PUFAs, 
and lower n-6/n-3 ratio, as compared to subjects with 
poor glycemic control. We hypothesize that the ratio of 
serum phospholipid n-6 to n-3 PUFAs may play a crucial 
role in control of glucose metabolism in high-risk T2DM 
patients. The clinical importance of n-6/n-3 ratio is still 
poorly understood. A few studies have demonstrated that 
the dietary n-6/n-3 ratio of 1:1 is the most beneficial for 
metabolic health, whereas it is approximately 15–20:1 in 
the present Western diet [34, 35].
In our study only LA was positively correlated with 
 HbA1c. The serum phospholipid LA levels were signifi-
cantly higher in subjects with worse glycemic control. 
This finding may at first seem surprising since n-6 PUFAs 
generally are associated with beneficial health effect. Sar-
tore et al. demonstrated that T2DM subjects have lower 
LA levels and higher concentrations of highly unsatu-
rated FAs [13]. Moreover, insulin sensitivity increases 
when saturated FAs are replaced by n-6 PUFAs [14].
It has been also demonstrated that LA in serum phos-
pholipids and cholesterol esters was inversely associated 
with visceral adipose tissue and trunk fat, both of which 
are well-known contributors to insulin resistance and 
metabolic disease [36]. There are evidence that higher 
Table 2 Baseline laboratory investigations (n = 74)
Data are given as number (percentage) for categorical variables and mean (± standard deviation) or median (IQR) for continuous variables
Italic values indicate significance of p value (p < 0.05)
eGFR (MDRD) estimated glomerular filtration rate calculated by the abbreviated MDRD equation, HbA1c glycated hemoglobin, HDL-C high-density lipoproteins, hsCRP 
high-sensitivity C-reactive protein, IL-6 interleukin-6, LDL-C low-density lipoproteins, TC total cholesterol, Tg triglycerides, TNFα tumor necrosis factor alpha
Variable n = 74 HbA1c < 7.0%
n = 38
HbA1c ≥ 7.0%
n = 36
p value
HbA1c (%) 7.0 (6.6; 7.5) 6.6 (6.5; 6.8) 7.5 (7.2; 8.3) < 0.0001
Insulin (µIU/ml) 21.5 (14.6; 33.6) 19.1 (14.6; 27. 9) 24.4 (14.8; 38.5) 0.15
C‑peptide (ng/ml) 3.25 ± 1.40 3.61 ± 1.47 2.87 ± 1.24 0.02
TC (mmol/l) 3.86 ± 0.91 3.69 ± 0.85 4.04 ± 0.95 0.10
LDL‑C (mmol/l) 1.91 (1.53; 2.64) 1.825 (1.45; 2.51) 1.99 (1.63; 2.90) 0.22
HDL‑C (mmol/l) 1.24 ± 0.38 1.28 ± 0.36 1.21 ± 0.40 0.75
Tg (mmol/l) 1.35 (1.12; 1.92) 1.375 (0.99; 1.91) 1.34 (1.14; 1.99) 0.57
Creatinine (µmol/l) 83.7 ± 22.0 82.9 ± 17.8 84.5 ± 25.9 0.77
eGFR (MDRD) (ml/min/1.73 m2) 78.3 (70.0; 90.0) 81.8 (70.0; 90.0) 78.0 (64.0; 90.0) 0.76
hsCRP (mg/l) 1.54 (0.73; 2.71) 1.33 (0.52; 2.43) 1.87 (0.85; 4.39) 0.02
IL‑6 (pg/ml) 1.99 (1.55; 2.79) 1.88 (1.36; 2.28) 2.17 (1.64; 3.13) 0.09
TNFα (pg/ml) 1.48 (1.28; 1.76) 1.43 (1.24; 1.68) 1.52 (1.40; 1.79) 0.22
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Table 3 Serum phospholipid fatty acids composition in the study patients
Data are given as number (percentage) for categorical variables and mean (± standard deviation) or median (IQR) for continuous variables
Italic values indicate significance of p value (p < 0.05)
AA arachidonic acid, ALA alpha-linolenic acid, DHA docosahexaenoic acid, EPA eicosapentaenoic acid, FAs fatty acids, LA linoleic acid, MUFAs monounsaturated fatty 
acids, PUFAs polyunsaturated fatty acids, SFAs saturated fatty acids
a The n-6/n-3 fatty acid ratio was calculated by measuring: linoleic, C18:2n-6; eicosadienoic, C20:2n-6; arachidonic, C20:4n-6 acids to estimate total n-6 PUFAs and 
alpha-linolenic, C18:3n-3; eicosapentaenoic, C20:5n-3; docosahexaenoic, C22:6n-3 acids to estimate the total n-3 PUFAs
Fatty acid HbA1c < 7.0%
n = 38
HbA1c ≥ 7.0%
n = 36
p value
SFAs
 C12:0 (µmol/l) 1.73 (1.14; 2.84) 2.25 (1.39; 3.31) 0.17
 C14:0 (µmol/l) 16.20 (15.09; 18.12) 18.31 (14.37; 20.92) 0.18
 C16:0 (µmol/l) 940.62 (833.71; 1022.22) 973.60 (868.19; 1074.23) 0.50
 C18:0 (µmol/l) 421.96 ± 92.87 439.14 ± 96.71 0.44
 C24:0 (µmol/l) 24.17 (19.31; 28.40) 24.695 (20.38; 30.34) 0.99
MUFAs
 C16:1 (µmol/l 15.06 (12.33; 21.72) 14.56 (12.00; 19.79) 0.60
 C18:1 (µmol/l) 270.77 (244.27; 332.28) 285.625 (246.25; 336.565) 0.75
n‑3 PUFAs
 C18:3; ALA (µmol/l) 5.75 (4.73; 8.48) 7.21 (5.22; 8.94) 0.26
 C20:5; EPA (µmol/l) 71.66 (48.65; 90.31) 48.55 (38.96; 66.86) 0.002
 C22:6; DHA (µmol/l) 303.11 (241.62; 355.04) 263.25 (208.77; 325.18) 0.07
n‑6 PUFAs
 C18:2; LA (µmol/l) 421.46 (343.43; 476.27) 471.02 (402.46; 546.30) 0.02
 C20:2 (µmol/l) 16.39 (13.24; 18.33) 18.21 (14.39; 22.26) 0.14
 C20:4; AA (µmol/l) 542.03 ± 95.38 561.92 ± 154.30 0.51
Total SFAs (µmol/l) 1439.66 ± 288.90 1431.66 ± 282.75 0.90
Total MUFAs (µmol/l) 286.15 (260.18; 356.12) 308.95 (261.43; 357.57) 0.77
Total n‑3 PUFAs (µmol/l) 378.16 (296.06; 436.75) 320.70 (260.36; 396.61) 0.02
Total n‑6 PUFAs (µmol/l) 986.24 ± 171.11 1065.54 ± 210.49 0.08
Total FAs (µmol/l) 3088.55 (2785.20; 3413.38) 3148.76 (2748.18; 3519.32) 0.65
n‑6/n‑3  ratioa 2.69 ± 0.78 3.32 ± 0.83 0.001
EPA/AA ratio 0.13 (0.07; 0.14) 0.10 (0.07; 0.12) 0.008
DHA/AA ratio 0.13 (0.09; 0.17) 0.50 (0.41; 0.59) 0.15
Table 4 Univariate and multivariate logistic regression analysis of poor glycemic control  (HbA1c ≥ 7.0%) in the study 
patients
AA arachidonic acid, CI confidence interval, EPA eicosapentaenoic acid, HbA1c glycated hemoglobin, hsCRP high-sensitivity C-reactive protein, LA linoleic acid, PUFAs 
polyunsaturated fatty acids, OR odds ratio, T2DM type 2 diabetes mellitus
Variable Univariate analysis Multivariate analysis
OR (95% CI) p value OR (95% CI) p value
Insulin therapy 5.70 (2.08–15.67) < 0.001
n‑6/n‑3 ratio 2.69 (1.41–5.14) 0.003 4.35 (1.72–10.96) 0.002
hsCRP (mg/l) 1.28 (1.01–1.62) 0.043 1.52 (1.04–2.21) 0.032
Total n‑6 PUFAs (µmol/l) 1.25 (1.04–1.50) 0.020
T2DM duration (years) 1.11 (1.02–1.21) 0.019 1.18 (1.04–1.32) 0.008
C18:2; LA (µmol/l) 1.01 (1.001–1.011) 0.037
C20:5; EPA (µmol/l) 0.98 (0.97–1.00) 0.050
Total n‑3 PUFAs (µmol/l) 0.76 (0.63–0.93) 0.007
C‑peptide (ng/ml) 0.66 (0.45–0.96) 0.028
EPA/AA ratio 0.001 (0.0001–0.51) 0.034
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levels of n-6 PUFAs in plasma phospholipids, in particu-
lar LA, are linked to a lower risk of T2DM [29, 37].
On the other hand, some epidemiological studies and 
animal models suggest that n-6 PUFAs may promote adi-
posity and influence metabolic processes in various tissues 
[38]. There are a number of ways by which n-6 PUFAs can 
adversely affect metabolic pathways: (1) promoting tissue 
AA accumulation and increased production of pro-inflam-
matory eicosanoids, (2) reduced conversion of ALA into 
EPA, (3) reduced production of anti-inflammatory eicosa-
noids from EPA and DHA [39]. It has been suggested that 
n-6 PUFAs incorporated into phospholipids may be more 
susceptible to oxidative stress compared to n-3 PUFAs [24]. 
In addition, the oxidized metabolites of LA (OXLAMs), 
including bioactive 9- and 13 hydroxy-octadecadienoic acid 
(9- and 13-HODE) and 9- and 13-oxo-octadecadienoic acid 
(9- and 13-oxoODE), exert several pro-inflammatory and 
pro-atherogenic properties [40]. Some studies showed that 
higher plasma phospholipid n-6 PUFAs were associated 
with increased arterial stiffness as measured by carotid-
femoral pulse wave velocity (cfPWV) [41, 42]. There is 
accumulating evidence from randomized controlled trials 
that replacement of dietary saturated FAs by LA signifi-
cantly lowers serum total cholesterol (mostly by reducing 
low-density lipoprotein cholesterol) but does not support 
the hypothesis that this translates to a lower risk of death 
from CAD or decreased all-cause mortality [40].
Furthermore, it has been reported that LA intake was 
inversely associated with leukocyte telomere length (LTL) 
in female participants of the Nurses’ Health Study [43]. 
As an indicator of oxidative stress, DNA damage and cel-
lular senescence, LTL has been postulated as a biomarker 
of aging and age-related chronic diseases, including CAD 
and T2DM [43, 44].
In our study, elevated levels of LA in serum phospho-
lipids of patients with poor glycemic control could be 
caused by higher dietary intake of LA/lower frequency 
of meals or by altered pathways of n-6 PUFA metabo-
lism. Unfortunately, we did not conduct a dietary survey 
in our patients. However, all participants were consulted 
by a cardiovascular physician and each patient received 
the same diet recommendations consistent with the Euro-
pean Society of Cardiology guidelines. Therefore, it seems 
unlikely, that the study patients with worse glycemic con-
trol had a different diet, particularly rich in linoleic acid, 
what could possibly result in higher concentrations of 
linoleic acid in serum phospholipids. We believe that 
higher serum phospholipid linoleic acid levels in patients 
with poor glycemic control could result from altered n-6 
PUFA metabolism. As the parent compound for the fam-
ily of n-6 PUFAs, LA can be elongated and desaturated to 
other n-6 PUFAs, such as γ-linolenic acid and AA. It has 
been reported that in diabetes, the fatty acid elongase and 
desaturase (i.e. Δ5- and Δ6-desaturase) activities decrease 
significantly, which may result in altered levels of PUFAs 
among patients with metabolic syndrome and T2DM 
[13, 45]. The desaturase enzymes are also regulated and 
modulated by many dietary and hormonal factors, includ-
ing insulin [13, 45]. However, exogenous insulin does not 
seem to significantly influence phospholipid FA composi-
tion and desaturase activities in patients with T2DM [13].
As previously reported, a high intake of LA may dis-
turb the metabolism and distribution of n-3 PUFAs [38]. 
It is well known that both LA and ALA compete for the 
same active site of microsomal ∆6-desaturase, the rate-
limiting enzyme in long-chain PUFA biosynthesis [27]. It 
is possible that higher serum phospholipid LA concen-
trations in patients with poor glycemic control contribute 
to decrease of ALA metabolism and reduced synthesis of 
EPA and DHA, resulting in increased n-6/n-3 ratio.
PUFAs and systemic inflammation
Numerous epidemiological and clinical studies showed 
that the high intake of n-3 PUFAs is associated with 
decreased inflammation [14]. Low-grade systemic 
inflammation as measured by serum concentrations of 
CRP is related to insulin resistance and ASCVD [46]. 
However, a potential mediating role of low-grade inflam-
mation in the association between FA composition and 
insulin resistance is still unclear [46].
It has been suggested that n-3 and n-6 PUFAs cause 
opposite effects on systemic inflammation [34]. The 
eicosanoids derived from n-3 PUFAs generally have anti-
inflammatory properties, while n-6 PUFA-derived lipid 
mediators are considered pro-inflammatory [47, 48]. LA 
is a precursor of AA, which may be converted to the pro-
inflammatory prostaglandin  E2  (PGE2) and leukotriene  B4 
[18]. On the contrary, eicosanoids derived from the EPA 
can down-regulate the biosynthesis of  PGE2 [18]. The 
anti-inflammatory effects of n-3 PUFAs are related, in 
large part, to competition between EPA and AA as sub-
strates for cyclooxygenases and to prevention of the con-
version of AA into potent pro-inflammatory eicosanoids 
[18]. Thus, a high n-6/n-3 ratio may promote inflamma-
tory diseases including ASCVD [16, 18]. The EPA/AA 
and DHA/AA ratios may reflect cardiovascular inflam-
mation in patients with ASCVD and remain established 
markers of cardiovascular events [16].
Furthermore, n-3 PUFAs can serve as alternative sub-
strates to produce less potent mediators, including 
3-series prostaglandins and thromboxanes, and 5-series 
leukotrienes [18]. Experimental studies showed that 
EPA and DHA are also substrates for production of pro-
resolving lipid mediators such as resolvins, maresins and 
protectins [18]. There is accumulating evidence that these 
bioactive compounds can influence glucose and insulin 
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homeostasis and directly exert cardioprotective actions 
in vivo [18].
Serum concentrations of CRP in Western populations 
have been positively associated with some saturated (e.g. 
stearic acid) and monounsaturated FAs (e.g. palmitoleic 
and oleic acids), but inversely associated with LA and n-3 
PUFAs such as ALA and EPA [49]. Kaska et al. found that 
both total saturated and monounsaturated FAs are posi-
tively correlated with serum hsCRP, whereas both n-6 
and n-3 PUFAs show inverse correlation with this marker 
in patients with  HbA1c levels < 7.0% [48].
Fig. 1 Eicosapentaenoic acid (EPA) concentration (a), docosahexaenoic acid (DHA) concentration (b), linoleic acid (LA) concentration (c), EPA to 
arachidonic acid (EPA/AA) ratio (d), total n‑3 PUFAs concentration (e), and n‑6 to n‑3 PUFA ratio (f) in serum phospholipids of the study patients
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In addition, Poudel-Tandukar et al. demonstrated that 
CRP levels in a Japanese working population increased 
with a decreasing proportion of ALA and an increasing 
proportion of palmitic acid in men, and with an increas-
ing proportion of dihomo-γ-linolenic acid in both sexes 
[49]. Similarly, studies among European populations have 
also disclosed an inverse association between serum ALA 
and CRP concentrations [49].
In our study, however, levels of saturated, monoun-
saturated and polyunsaturated fatty acids in serum phos-
pholipids were not significantly associated with systemic 
inflammatory markers.
Limitations
Our study has several limitations. First, the cross-sec-
tional nature of the study did not allow us to infer cau-
sality. Second, the dietary fat intake was not assessed 
precisely, as our participants were provided dietary 
advice regarding low-fat and low-carbohydrate foods 
and caloric values. Therefore, we cannot unambiguously 
exclude the influence of a diet on the observed results. 
Finally, the sample size was relatively small in the pre-
sent study and a larger sample would have provided more 
robust findings.
Conclusions
In conclusion, this study showed that glycemic control in 
high-risk T2DM patients with ASCVD was significantly 
associated with unfavorable serum phospholipid n-6/n-3 
PUFA ratio and greater systemic inflammation. There 
was no relevant relationship between serum phospho-
lipid FA composition and systemic inflammation. These 
results confirm the beneficial effect of long-chain n-3 
PUFAs in T2DM and support current recommendations 
for regular fish consumption.
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